Who are C) primary immunizations with Ixiaro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EV71 (inoculation vaccine), HAVpur Junior, two doses enterovirus 71 vaccine, Control Vaccine, EV71 +SIV, COVAX only (1st and 2nd dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/c-primary-immunizations-with-ixiaro.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

C) primary immunizations with Ixiaro — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

C) primary immunizations with Ixiaro (C) primary immunizations with Ixiaro) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine Japanese encephalitis virus envelope and non-structural proteins Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

C) primary immunizations with Ixiaro (C) primary immunizations with Ixiaro) — Helsinki University Central Hospital. Ixiaro is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
C) primary immunizations with Ixiaro TARGET	C) primary immunizations with Ixiaro	Helsinki University Central Hospital	phase 3	Inactivated viral vaccine	Japanese encephalitis virus envelope and non-structural proteins
EV71 (inoculation vaccine)	EV71 (inoculation vaccine)	Shandong Province Centers for Disease Control and Prevention	marketed	inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens
HAVpur Junior	HAVpur Junior	Crucell Holland BV	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
two doses enterovirus 71 vaccine	two doses enterovirus 71 vaccine	Beijing Chaoyang District Centre for Disease Control and Prevention	marketed	inactivated viral vaccine	Enterovirus 71 viral antigens
Control Vaccine	Control Vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine
EV71 +SIV	EV71 +SIV	Zhejiang Provincial Center for Disease Control and Prevention	marketed	Inactivated viral vaccine
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). C) primary immunizations with Ixiaro — Competitive Intelligence Brief. https://druglandscape.com/ci/c-primary-immunizations-with-ixiaro. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing